Fang G X, Li Z, Su C, Hu G H
Department of Pediatrics, Jinhua Maternal and Child Health Hospital, Jinhua, 321000, China.
Department of Paediatrics, Jinhua Polytechnic Medical College Pediatrics.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Nov 5;31(21):1649-1652. doi: 10.13201/j.issn.1001-1781.2017.21.007.
To study the treatment efficacy of Saccharomyces boulardii combined with Cetirizine Hydrochloride of children with allergic rhinitis (AR) and the influence of IFN-γ and interleukin-4 (IL-4) Level in serum.Ninty cases of children were randomly divided into observation group and control group (both n=45).The control group with levocetirizine hydrochloride drops, 5 mL/time for 2-6 years old, 10 mL/time for >6 years old , qd oral. Group based on the combination of Saccharomyces boulardi, 0.25 g/time for <3 years old, qd, > 3 years old, 0.25 g, bid. Four weeks for a course of treatment, and set 30 cases for the health group.The level of serum IFN-γ was significantly lower in the two groups than in the healthy group ( < 0.01), while the level of IL-4 was significantly higher than that of the healthy group ( < 0.01). After treatment, the levels of IFN-γ of both groups were up-regulated And the level of IL-4 were down-regulated , but the effect of the treatment group was more obvious ( < 0.01). The total effective rate was 91.11% in the observation group, which was significantly higher than that in the control group (68.89%,χ2=6.94, < 0.01). After treatment, the symptom scores of the two groups were lower than those before treatment, but the observation group was significantly lower than the control group ( < 0.01). Compared with the control group, the observation group was significantly better than the control group ( < 0.01).The combination of Saccharomyces boulardi and levocetirine hydrochloride in the treatment of children with AR has obvious clinical efficacy, and its mechanism may be related to the correction of interferon IFN-γ and IL-4.
探讨布拉氏酵母菌联合盐酸西替利嗪治疗儿童变应性鼻炎（AR）的疗效及对血清干扰素-γ（IFN-γ）和白细胞介素-4（IL-4）水平的影响。将90例儿童随机分为观察组和对照组（各45例）。对照组口服盐酸左西替利嗪滴剂，2～6岁5 mL/次，＞6岁10 mL/次，qd。观察组在对照组基础上加用布拉氏酵母菌，＜3岁0.25 g/次，qd，＞3岁0.25 g，bid。4周为1个疗程，另设健康组30例。两组血清IFN-γ水平均显著低于健康组（P＜0.01），而IL-4水平显著高于健康组（P＜0.01）。治疗后，两组IFN-γ水平上调，IL-4水平下调，但治疗组效果更明显（P＜0.01）。观察组总有效率为91.11%，显著高于对照组（68.89%，χ2 = 6.94，P＜0.01）。治疗后，两组症状评分均低于治疗前，但观察组显著低于对照组（P＜0.01）。与对照组比较，观察组疗效显著优于对照组（P＜0.01）。布拉氏酵母菌与盐酸左西替利嗪联合治疗儿童AR具有明显临床疗效，其机制可能与纠正IFN-γ和IL-4有关。
